BR112012027303A2 - comprimido de desintegração oral contendo acarbose - Google Patents

comprimido de desintegração oral contendo acarbose

Info

Publication number
BR112012027303A2
BR112012027303A2 BR112012027303A BR112012027303A BR112012027303A2 BR 112012027303 A2 BR112012027303 A2 BR 112012027303A2 BR 112012027303 A BR112012027303 A BR 112012027303A BR 112012027303 A BR112012027303 A BR 112012027303A BR 112012027303 A2 BR112012027303 A2 BR 112012027303A2
Authority
BR
Brazil
Prior art keywords
tablet containing
oral
acarbose
crumbling
disintegrating tablet
Prior art date
Application number
BR112012027303A
Other languages
English (en)
Inventor
Schneeweis Axel
Laich Tobias
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112012027303A2 publication Critical patent/BR112012027303A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

comprimido de desintegração oral contendo acarbose. era um objetivo da presente invenção fornecer um comprimido de desintegração oral (odt) para o inibidor de glicosidase acarbose. este objetivo é atingido com um comprimido de desintegração oral contendo 1-30% de acarbose e 40-90% de veículo solúvel em água. a fim de obter as propriedades desejadas, os componentes precisam ser pré-compactados e pré-misturados com um veículo insolúvel.
BR112012027303A 2010-04-27 2011-04-26 comprimido de desintegração oral contendo acarbose BR112012027303A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161114 2010-04-27
PCT/EP2011/056587 WO2011134962A2 (en) 2010-04-27 2011-04-26 Orally disintegrating tablet containing acarbose

Publications (1)

Publication Number Publication Date
BR112012027303A2 true BR112012027303A2 (pt) 2017-10-24

Family

ID=44344015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027303A BR112012027303A2 (pt) 2010-04-27 2011-04-26 comprimido de desintegração oral contendo acarbose

Country Status (26)

Country Link
US (1) US20130131003A1 (pt)
EP (1) EP2563329B1 (pt)
JP (1) JP5944378B2 (pt)
KR (1) KR101788350B1 (pt)
CN (2) CN106924199A (pt)
AU (1) AU2011247642C1 (pt)
BR (1) BR112012027303A2 (pt)
CA (1) CA2797365A1 (pt)
CL (1) CL2012003011A1 (pt)
CO (1) CO6640213A2 (pt)
CR (1) CR20120548A (pt)
CU (1) CU20120152A7 (pt)
DO (1) DOP2012000277A (pt)
EC (1) ECSP12012279A (pt)
ES (1) ES2623025T3 (pt)
GT (1) GT201200290A (pt)
IL (1) IL222368B (pt)
MX (1) MX348865B (pt)
MY (1) MY179724A (pt)
NZ (1) NZ603199A (pt)
PE (1) PE20130403A1 (pt)
SG (2) SG10201505844WA (pt)
SI (1) SI2563329T1 (pt)
TW (1) TWI556823B (pt)
UA (1) UA111155C2 (pt)
WO (1) WO2011134962A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201100150A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Suda çözünür dozaj formları
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
WO2013115738A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Micronized acarbose
EP2890370B1 (en) * 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
MX2017007493A (es) * 2014-12-17 2018-01-26 Empros Pharma Ab Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
CN105213341A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种阿卡波糖片及其制备方法
CN113081984B (zh) * 2021-04-19 2023-06-02 北京阳光诺和药物研究股份有限公司 一种阿卡波糖口崩片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR100682836B1 (ko) * 2004-12-06 2007-02-15 엘지전자 주식회사 유기 전계 발광 소자
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
WO2007099908A1 (ja) * 2006-02-27 2007-09-07 Matsushita Electric Industrial Co., Ltd. ウェアラブル端末、および、携帯撮像収音装置、およびそれらを実現する装置、方法、プログラム
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN101411715B (zh) * 2007-10-19 2012-03-28 杭州华东医药集团生物工程研究所有限公司 含有阿卡波糖的药物组合物
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
WO2009071219A2 (en) * 2007-12-08 2009-06-11 Bayer Schering Pharma Aktiengesellschaft Oral dispersable tablet
WO2009086046A1 (en) * 2007-12-21 2009-07-09 Eurand, Inc. Orally disintegrating tablet compositions of temazepam
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido

Also Published As

Publication number Publication date
AU2011247642B2 (en) 2015-05-14
NZ603199A (en) 2014-05-30
US20130131003A1 (en) 2013-05-23
AU2011247642C1 (en) 2015-11-12
ECSP12012279A (es) 2012-11-30
WO2011134962A3 (en) 2012-05-03
CO6640213A2 (es) 2013-03-22
MY179724A (en) 2020-11-11
PE20130403A1 (es) 2013-04-13
KR101788350B1 (ko) 2017-10-19
EP2563329A2 (en) 2013-03-06
AU2011247642A1 (en) 2012-11-08
MX2012012459A (es) 2012-11-21
TWI556823B (zh) 2016-11-11
CN102905687A (zh) 2013-01-30
SG10201505844WA (en) 2015-09-29
CA2797365A1 (en) 2011-11-03
GT201200290A (es) 2014-09-24
IL222368B (en) 2018-11-29
JP2013525404A (ja) 2013-06-20
CN106924199A (zh) 2017-07-07
KR20130062926A (ko) 2013-06-13
SG184851A1 (en) 2012-11-29
WO2011134962A2 (en) 2011-11-03
IL222368A0 (en) 2012-12-31
TW201141490A (en) 2011-12-01
SI2563329T1 (sl) 2017-05-31
MX348865B (es) 2017-07-03
UA111155C2 (uk) 2016-04-11
CU20120152A7 (es) 2014-02-28
CL2012003011A1 (es) 2013-04-19
CR20120548A (es) 2013-03-11
ES2623025T3 (es) 2017-07-10
EP2563329B1 (en) 2017-04-12
JP5944378B2 (ja) 2016-07-05
DOP2012000277A (es) 2012-12-15

Similar Documents

Publication Publication Date Title
BR112012027303A2 (pt) comprimido de desintegração oral contendo acarbose
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
TWD163155S (zh) 耳機
TWD158344S (zh) 閂鎖組件
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
IN2015DN03795A (pt)
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
BR112012032033A2 (pt) novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
BR112015009871A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
UA109037C2 (uk) Триазолопіридини
UA116654C2 (uk) Похідні пурину як агоністи канабіноїдного рецептора св2
TR201010683A1 (tr) Vildagliptin formülasyonları.
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
TR201104977A1 (tr) Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.